Wire · opportunities
Teva wins FDA approval for once-monthly olanzapine injection
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
Teva Pharmaceuticals received FDA approval for WELTRUZA, a once-monthly injectable olanzapine treatment for schizophrenia that uses Medincell's SteadyTeq technology for sustained drug release without loading doses or oral supplementation.
This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it between 9 Oct 2026 and 13 Oct 2026.
◆ ◆ The Wire takeaway
You can now access a new treatment option that improves adherence by eliminating daily dosing for schizophrenia. This FDA approval creates a rare entry point for sustained-release injectables in mental health, opening fast commercial potential.
◆ Coverage
20 sources · first reported 9 Oct 2026 · latest 13 Oct 2026
◆ Topics